Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -67.20
- Piotroski Score 3.00
- Grade Buy
- Symbol (NBY)
- Company NovaBay Pharmaceuticals, Inc.
- Price $0.68
- Changes Percentage (-4.03%)
- Change -$0.03
- Day Low $0.68
- Day High $0.72
- Year High $11.55
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$120.40
- Trailing P/E Ratio -0.02
- Forward P/E Ratio -0.02
- P/E Growth -0.02
- Net Income $-9,640,000
Income Statement
Quarterly
Annual
Latest News of NBY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Hornby Pretax Loss Widens; Says Turnaround Strategy Progressing Well
Hornby reported a widened pretax loss in the first half of the fiscal year, but is progressing well with its turnaround plan. The company reduced costs through job cuts and restructuring, leading to i...
By MarketWatch | 2 days ago -
Hornby Confirms Full-Year Guidance as Sales and Profit Grow
Hornby reported increased sales and gross profit for the five months up to August, but slightly below internal forecasts due to shipping delays. The models and collectables group confirmed its full-ye...
By MarketWatch | 2 months ago -
Shooting at Allenby Bridge Crossing between West Bank and Jordan kills 3 Israelis
Three Israeli civilians were killed at the West Bank-Jordan border by a gunman. Israeli PM Netanyahu condemned the attack, linking it to Iran. Hamas praised the attack, while Jordan investigates. The ...
By CBS News | 2 months ago
